Comparison 8. Gluco+IFN versus Control+IFN (human and recombinant IFN) at maximal follow‐up.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Loss of HBeAg	13	790	Peto Odds Ratio (Peto, Fixed, 95% CI)	1.41 [1.03, 1.92]
1.1 Human IFN	5	419	Peto Odds Ratio (Peto, Fixed, 95% CI)	1.60 [1.06, 2.42]
1.2 Recombinant IFN	8	371	Peto Odds Ratio (Peto, Fixed, 95% CI)	1.19 [0.75, 1.91]
2 HBeAg to anti‐HBe seroconversion	8	554	Peto Odds Ratio (Peto, Fixed, 95% CI)	1.26 [0.87, 1.82]
2.1 Human IFN	3	308	Peto Odds Ratio (Peto, Fixed, 95% CI)	1.41 [0.86, 2.29]
2.2 Recombinant IFN	5	246	Peto Odds Ratio (Peto, Fixed, 95% CI)	1.09 [0.62, 1.91]
3 Loss of HBsAg	11	705	Peto Odds Ratio (Peto, Fixed, 95% CI)	1.41 [0.77, 2.59]
3.1 Human IFN	4	343	Peto Odds Ratio (Peto, Fixed, 95% CI)	2.88 [1.16, 7.17]
3.2 Recombinant IFN	7	362	Peto Odds Ratio (Peto, Fixed, 95% CI)	0.79 [0.35, 1.79]
4 Loss of HBV DNA	13	790	Peto Odds Ratio (Peto, Fixed, 95% CI)	1.51 [1.12, 2.05]
4.1 Human IFN	5	419	Peto Odds Ratio (Peto, Fixed, 95% CI)	1.85 [1.23, 2.79]
4.2 Recombinant IFN	8	371	Peto Odds Ratio (Peto, Fixed, 95% CI)	1.18 [0.75, 1.87]
5 Normalisation of ALT or AST activities	9	587	Peto Odds Ratio (Peto, Fixed, 95% CI)	1.13 [0.79, 1.62]
5.1 Human IFN	4	384	Peto Odds Ratio (Peto, Fixed, 95% CI)	1.07 [0.67, 1.71]
5.2 Recombinant IFN	5	203	Peto Odds Ratio (Peto, Fixed, 95% CI)	1.22 [0.70, 2.15]